Literature DB >> 21632811

Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence.

Lourdes Ibáñez1, Abel López-Bermejo, Marta Díaz, Maria Victoria Marcos, Francis de Zegher.   

Abstract

CONTEXT: Girls with a combined history of low(-normal) birth weight (LBW) and precocious pubarche (PP) are at high risk to develop polycystic ovary syndrome (PCOS).
OBJECTIVE: The objective of the study was to compare the capacity of early vs. late metformin treatment to prevent adolescent PCOS.
DESIGN: This was a randomized, open-label study over 7 yr.
SETTING: The study was conducted at a university hospital. PATIENTS: Thirty-eight LBW-PP girls were followed up from the mean age 8 until age 15 yr. INTERVENTION: Early metformin (study yr 1-4; age 8-12 yr) vs. late metformin (yr 6; age 13-14 yr). MAIN OUTCOME MEASURES: Measures included height; weight; hirsutism score; menstrual cycle; endocrine-metabolic screening (fasting; follicular phase); C-reactive protein; body composition (absorptiometry); abdominal fat partitioning (magnetic resonance imaging); ovarian morphology (ultrasound); PCOS (National Institutes of Health and Androgen Excess Society definitions) after yr 7 (all girls thus untreated for at least 1 yr).
RESULTS: None of the girls dropped out of the study. At age 15 yr, early-metformin girls were taller (4 cm), were in a less proinflammatory state, and had less central fat due to reductions in visceral and hepatic fat. Hirsutism, androgen excess, oligomenorrhea, and PCOS were between 2- and 8-fold more prevalent in late- than early-treated girls. Abdominal adiposity was the first variable to diverge (at age 8-10 yr) between girls without vs. with PCOS at age 15 yr.
CONCLUSIONS: In LBW-PP girls, early metformin therapy was found to prevent or delay the development of hirsutism, androgen excess, oligomenorrhea, and PCOS more effectively than late metformin. The time window of late childhood and early puberty may be more critical for the development, and thus for the prevention, of adolescent PCOS than the first years beyond menarche.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632811     DOI: 10.1210/jc.2011-0555

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

Review 1.  PCOS in adolescence and type 2 diabetes.

Authors:  Anne-Marie Carreau; Jean-Patrice Baillargeon
Journal:  Curr Diab Rep       Date:  2015-01       Impact factor: 4.810

Review 2.  Polycystic ovary syndrome throughout a woman's life.

Authors:  José Bellver; Luis Rodríguez-Tabernero; Ana Robles; Elkin Muñoz; Francisca Martínez; José Landeras; Juan García-Velasco; Juan Fontes; Mónica Álvarez; Claudio Álvarez; Belén Acevedo
Journal:  J Assist Reprod Genet       Date:  2017-09-27       Impact factor: 3.412

Review 3.  Ontogeny of polycystic ovary syndrome and insulin resistance in utero and early childhood.

Authors:  David H Abbott; Fida Bacha
Journal:  Fertil Steril       Date:  2013-07       Impact factor: 7.329

Review 4.  Cardiometabolic aspects of the polycystic ovary syndrome.

Authors:  Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert
Journal:  Endocr Rev       Date:  2012-07-24       Impact factor: 19.871

Review 5.  Impact of metformin on reproductive tissues: an overview from gametogenesis to gestation.

Authors:  Michael J Bertoldo; Melanie Faure; Joelle Dupont; Pascal Froment
Journal:  Ann Transl Med       Date:  2014-06

Review 6.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

7.  Update: consequences of abnormal fetal growth.

Authors:  Steven D Chernausek
Journal:  J Clin Endocrinol Metab       Date:  2012-01-11       Impact factor: 5.958

8.  Comparing the Effects of Agnugol and Metformin on Oligomenorrhea in Patients with Polycystic Ovary Syndrome: A Randomized Clinical Trial.

Authors:  Arezoo Shayan; Seyedeh Zahra Masoumi; Fatemeh Shobeiri; Shahin Tohidi; Arash Khalili
Journal:  J Clin Diagn Res       Date:  2016-12-01

Review 9.  Reproductive neuroendocrine dysfunction in polycystic ovary syndrome: insight from animal models.

Authors:  Alison V Roland; Suzanne M Moenter
Journal:  Front Neuroendocrinol       Date:  2014-04-18       Impact factor: 8.606

10.  Metabolic regulation of female puberty via hypothalamic AMPK-kisspeptin signaling.

Authors:  Juan Roa; Alexia Barroso; Francisco Ruiz-Pino; Maria Jesus Vázquez; Patricia Seoane-Collazo; Noelia Martínez-Sanchez; David García-Galiano; Tuncay Ilhan; Rafael Pineda; Silvia León; Maria Manfredi-Lozano; Violeta Heras; Matti Poutanen; Juan M Castellano; Francisco Gaytan; Carlos Diéguez; Leonor Pinilla; Miguel López; Manuel Tena-Sempere
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.